Articles Tagged: gene therapy

1 article found

Precision Without Cuts: How Next‑Gen CRISPR Could Rewire the Fight Against Huntington’s Disease

Imagine treating a devastating brain disorder not by smashing the genome with molecular hammers, but by whispering precise instructions to the cell—dialing down a toxic message, muffling a faulty gene’s output, or rewriting a single letter so a protein breaks less destructively. That vision is taking shape in Huntington’s disease (HD), a fatal, inherited neurodegenerative condition caused by expanded CAG repeats in the huntingtin (HTT) gene on chromosome 4p16.3. Normal alleles carry ≈9–35 repeats; pathogenic alleles typically carry ≥40, producing a mutant protein prone to misfolding and toxic fragmentation. Researchers are now converging on three complementary, double‑strand break (DSB)‑free strategies that promise to lower risk while preserving precision: RNA targeting with Cas13d, CRISPR interference (CRISPRi) to repress transcription without cutting DNA, and in vivo base editing to reprogram HTT splicing toward less toxic isoforms. According to “An RNA‑targeting CRISPR–Cas13d system alleviates disease‑related phenotypes in Huntington’s disease models,” an allele‑sensitive Cas13d construct delivered to the striatum selectively reduced mutant HTT (mHTT) transcripts and improved motor behavior, with benefits persisting for at least eight months in mice. “DNA double‑strand break‑free CRISPR interference delays Huntington’s disease progression in mice” shows that dCas9‑based repression can delay disease progression and protect striatal neurons while sparing more wild‑type HTT expression in human cell models. Meanwhile, “In vivo CRISPR base editing for treatment of Huntington’s disease” reports a screen of 141 base editor variants to alter splice signals around exon 13, yielding HTT isoforms more resistant to caspase‑6 cleavage. The through line is clear: precision without permanent DNA cuts could move HD from intractable to programmable, with a safety profile that changes the clinical calculus for first‑in‑human gene therapies.

Huntington’s diseaseHTTCAG repeats+11 more